João Magalhães Pina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
João Magalhães Pina has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- João Ferreira Guerra
Hospital de Sao Jose, Centro Hospitalar e Universitário de Lisboa Central, Lisbon, Portugal
2 shared publications João Guerra
Hospital Cruz Vermelha, Portugal
2 shared publications- Luís Campos Pinheiro
Hospital de Sao Jose, Centro Hospitalar e Universitário de Lisboa Central, Lisbon, Portugal
2 shared publications - Miguel Lança
National Reference Laboratory for Influenza and Other Respiratory Viruses, National Institute of Health Doutor Ricardo Jorge, Portugal; NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisboa, Portugal
2 shared publications - Vanessa Andrade
Hospital de Sao Jose, Centro Hospitalar e Universitário de Lisboa Central, Lisbon, Portugal
2 shared publications - Ana Rita Gomes
Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 14 August 2026
- Published by Associacao Portuguesa de Urologia in APU Journal
- Vol. 40 (1) , 6-7
Rooted in Memory, Open to the World
- 14 August 2026
- Published by Associacao Portuguesa de Urologia in APU Journal
- Vol. 40 (1) , 6-7
Open AccessRooted in Memory, Open to the World
- Open Access
- 1 June 2026
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 52 (3)
Is there still a role for systematic biopsy after targeted biopsy for the detection of clinically significant prostate cancer in MRI suspicious lesions?
Purpose: The combination of systematic biopsy (SB) and MRI-targeted biopsy (TB) is the current approach for prostate cancer (PCa) diagnosis; however, the clinical benefit of including SB remains controversial. This study aimed to determine whether SB adds value beyond TB in detecting clinically significant prostate cancer (csPCa) in men with suspicious lesions. Materials and Methods: Retrospective, single-center study conducted between January 2019 and September 2023. It enrolled men with suspicious lesions identified on multiparametric MRI (PI-RADS≥3) who had undergone combined biopsy (TB+SB). Sociodemographic and clinical data were secondarily collected. csPCa was defined when ISUP≥2. Results: This study included 997 men with a median age of 68 years, of whom 497 had a negative prior biopsy. The TB+SB approach identified 53.0% of PCa and 36.8% of csPCa cases. TB alone significantly outperformed SB in identifying csPCa, with detection rates of 34.8% vs. 10.3%, respectively, missing only 4.8% of PCa diagnosis—most of which were low-grade tumors. SB contributed marginally, identifying additional csPCa cases in 1.4% of patients. In patients with a prior negative biopsy, the addition of SB to TB only accounted for 12.5% of PCa diagnosis. Limitations include the study single-center design, restricting generalizability, and the lack of whole-mount prostatectomy for histological confirmation. Conclusions: In conclusion, SB adds limited diagnostic value, with TB alone being sufficient for detecting csPCa cases in patients with MRI-visible lesions. The results suggest that SB may be safely omitted in selected patients to reduce biopsy burden and lead to better clinical outcomes.
- 1 June 2026
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 52 (3)
Open AccessIs there still a role for systematic biopsy after targeted biopsy for the detection of clinically significant prostate cancer in MRI suspicious lesions?
Purpose: The combination of systematic biopsy (SB) and MRI-targeted biopsy (TB) is the current approach for prostate cancer (PCa) diagnosis; however, the clinical benefit of including SB remains controversial. This study aimed to determine whether SB adds value beyond TB in detecting clinically significant prostate cancer (csPCa) in men with suspicious lesions. Materials and Methods: Retrospective, single-center study conducted between January 2019 and September 2023. It enrolled men with suspicious lesions identified on multiparametric MRI (PI-RADS≥3) who had undergone combined biopsy (TB+SB). Sociodemographic and clinical data were secondarily collected. csPCa was defined when ISUP≥2. Results: This study included 997 men with a median age of 68 years, of whom 497 had a negative prior biopsy. The TB+SB approach identified 53.0% of PCa and 36.8% of csPCa cases. TB alone significantly outperformed SB in identifying csPCa, with detection rates of 34.8% vs. 10.3%, respectively, missing only 4.8% of PCa diagnosis—most of which were low-grade tumors. SB contributed marginally, identifying additional csPCa cases in 1.4% of patients. In patients with a prior negative biopsy, the addition of SB to TB only accounted for 12.5% of PCa diagnosis. Limitations include the study single-center design, restricting generalizability, and the lack of whole-mount prostatectomy for histological confirmation. Conclusions: In conclusion, SB adds limited diagnostic value, with TB alone being sufficient for detecting csPCa cases in patients with MRI-visible lesions. The results suggest that SB may be safely omitted in selected patients to reduce biopsy burden and lead to better clinical outcomes.
- Open Access
- 1 January 2026
- Vol. 52 (3)
Is there still a role for systematic biopsy after targeted biopsy for the detection of clini-cally significant prostate cancer in MRI suspicious lesions?
The combination of systematic biopsy (SB) and MRI-targeted biopsy (TB) is the current approach for prostate cancer (PCa) diagnosis; however, the clinical benefit of including SB remains controversial. This study aimed to determine whether SB adds value beyond TB in detecting clinically significant prostate cancer (csPCa) in men with suspicious lesions. Retrospective, single-center study conducted between January 2019 and September 2023. It enrolled men with suspicious lesions identified on multiparametric MRI (PI-RADS≥3) who had undergone combined biopsy (TB+SB). Sociodemographic and clinical data were secondarily collected. csPCa was defined when ISUP≥2. This study included 997 men with a median age of 68 years, of whom 497 had a negative prior biopsy. The TB+SB approach identified 53.0% of PCa and 36.8% of csPCa cases. TB alone significantly outperformed SB in identifying csPCa, with detection rates of 34.8% vs. 10.3%, respectively, missing only 4.8% of PCa diagnosis-most of which were low-grade tumors. SB contributed marginally, identifying additional csPCa cases in 1.4% of patients. In patients with a prior negative biopsy, the addition of SB to TB only accounted for 12.5% of PCa diagnosis. Limitations include the study single-center design, restricting generalizability, and the lack of whole-mount prostatectomy for histological confirmation. In conclusion, SB adds limited diagnostic value, with TB alone being sufficient for detecting csPCa cases in patients with MRI-visible lesions. The results suggest that SB may be safely omitted in selected patients to reduce biopsy burden and lead to better clinical outcomes.
- 1 January 2026
- Vol. 52 (3)
Open AccessIs there still a role for systematic biopsy after targeted biopsy for the detection of clini-cally significant prostate cancer in MRI suspicious lesions?
The combination of systematic biopsy (SB) and MRI-targeted biopsy (TB) is the current approach for prostate cancer (PCa) diagnosis; however, the clinical benefit of including SB remains controversial. This study aimed to determine whether SB adds value beyond TB in detecting clinically significant prostate cancer (csPCa) in men with suspicious lesions. Retrospective, single-center study conducted between January 2019 and September 2023. It enrolled men with suspicious lesions identified on multiparametric MRI (PI-RADS≥3) who had undergone combined biopsy (TB+SB). Sociodemographic and clinical data were secondarily collected. csPCa was defined when ISUP≥2. This study included 997 men with a median age of 68 years, of whom 497 had a negative prior biopsy. The TB+SB approach identified 53.0% of PCa and 36.8% of csPCa cases. TB alone significantly outperformed SB in identifying csPCa, with detection rates of 34.8% vs. 10.3%, respectively, missing only 4.8% of PCa diagnosis-most of which were low-grade tumors. SB contributed marginally, identifying additional csPCa cases in 1.4% of patients. In patients with a prior negative biopsy, the addition of SB to TB only accounted for 12.5% of PCa diagnosis. Limitations include the study single-center design, restricting generalizability, and the lack of whole-mount prostatectomy for histological confirmation. In conclusion, SB adds limited diagnostic value, with TB alone being sufficient for detecting csPCa cases in patients with MRI-visible lesions. The results suggest that SB may be safely omitted in selected patients to reduce biopsy burden and lead to better clinical outcomes.
- Open Access
- 5 October 2024
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 4(84),p. 17-22
Renal carcinoma associated with end-stage kidney disease: A case series from a tertiary Portuguese hospital
End-stage kidney disease (ESKD) is associated with a higher incidence of renal cell carcinoma (RCC). Here we report a case series of 56 patients with ESKD who underwent radical nephrectomy for suspected renal masses at a tertiary hospital in Portugal from January 2017 to January 2024. Patient records were reviewed retrospectively to collect clinical, surgical, and pathological data. Among these patients, 12 had benign tumors, while 44 were diagnosed with malignant tumors, accounting for approximately 78.5% of the cohort. The histological analysis revealed the following distribution: clear cell RCC (20 cases, 45%), papillary RCC (11 cases, 25%), ACKD-associated RCC (6 cases, 14%), clear cell papillary RCC (4 cases, 9%), and chromophobe RCC (3 cases, 7%). Notably, the majority of patients (95.5%) had stage I malignant tumors, yet the prognosis for patients with ESKD was poorer compared to non-ESKD patients, with 7 patients succumbing during the follow-up period. This study underscores the complex relationship between ESKD and RCC, highlighting the challenges in diagnosis and management. Despite regular monitoring leading to early detection of tumors, the overall prognosis remains adversely affected by the compromised immune status and comorbid conditions prevalent in this population. The findings call for enhanced surveillance and personalized management strategies for RCC in patients with ESKD.
- 5 October 2024
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 4(84),p. 17-22
Open AccessRenal carcinoma associated with end-stage kidney disease: A case series from a tertiary Portuguese hospital
End-stage kidney disease (ESKD) is associated with a higher incidence of renal cell carcinoma (RCC). Here we report a case series of 56 patients with ESKD who underwent radical nephrectomy for suspected renal masses at a tertiary hospital in Portugal from January 2017 to January 2024. Patient records were reviewed retrospectively to collect clinical, surgical, and pathological data. Among these patients, 12 had benign tumors, while 44 were diagnosed with malignant tumors, accounting for approximately 78.5% of the cohort. The histological analysis revealed the following distribution: clear cell RCC (20 cases, 45%), papillary RCC (11 cases, 25%), ACKD-associated RCC (6 cases, 14%), clear cell papillary RCC (4 cases, 9%), and chromophobe RCC (3 cases, 7%). Notably, the majority of patients (95.5%) had stage I malignant tumors, yet the prognosis for patients with ESKD was poorer compared to non-ESKD patients, with 7 patients succumbing during the follow-up period. This study underscores the complex relationship between ESKD and RCC, highlighting the challenges in diagnosis and management. Despite regular monitoring leading to early detection of tumors, the overall prognosis remains adversely affected by the compromised immune status and comorbid conditions prevalent in this population. The findings call for enhanced surveillance and personalized management strategies for RCC in patients with ESKD.
- Open Access
- 5 August 2024
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 3(83),p. 3-7
Unraveling Zinner Syndrome: Insights from a distinct case
Zinner Syndrome (ZS) is a rare congenital malformation characterized by a triad of unilateral renal agenesis, ipsilateral seminal vesicle cyst, and ejaculatory duct obstruction. Typically discovered incidentally in the second to fourth decades of life, it presents with varied symptoms, including lower urinary tract symptoms, painful ejaculation, hemospermia, perineal pain, and infertility in 45% of cases. This article describes the case of ZS, highlighting the diagnostic and management approaches. Diagnosis relies on imaging techniques: ultrasound for initial assessment, computed tomography (CT) for detailed anatomical information and magnetic resonance imaging (MRI) as the gold standard for its superior soft-tissue contrast. Treatment depends on symptom severity and cyst size, ranging from conservative management for asymptomatic patients to surgical intervention for symptomatic cases. The primary surgical treatment involves the removal of the seminal vesicle cysts, which can effectively relieve symptoms such as pain, urinary discomfort, and ejaculatory dysfunction, thereby significantly enhancing the patient's quality of life. Minimally invasive laparoscopic or robotic surgery is preferred for its reduced morbidity and shorter recovery time. Infertility management includes surgical relief of ejaculatory duct obstruction and assisted reproductive technologies when necessary. Regular follow-up is essential for monitoring recurrences. Future research should focus on long-term outcomes and standardized management protocols to improve patient quality of life.
- 5 August 2024
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 3(83),p. 3-7
Open AccessUnraveling Zinner Syndrome: Insights from a distinct case
Zinner Syndrome (ZS) is a rare congenital malformation characterized by a triad of unilateral renal agenesis, ipsilateral seminal vesicle cyst, and ejaculatory duct obstruction. Typically discovered incidentally in the second to fourth decades of life, it presents with varied symptoms, including lower urinary tract symptoms, painful ejaculation, hemospermia, perineal pain, and infertility in 45% of cases. This article describes the case of ZS, highlighting the diagnostic and management approaches. Diagnosis relies on imaging techniques: ultrasound for initial assessment, computed tomography (CT) for detailed anatomical information and magnetic resonance imaging (MRI) as the gold standard for its superior soft-tissue contrast. Treatment depends on symptom severity and cyst size, ranging from conservative management for asymptomatic patients to surgical intervention for symptomatic cases. The primary surgical treatment involves the removal of the seminal vesicle cysts, which can effectively relieve symptoms such as pain, urinary discomfort, and ejaculatory dysfunction, thereby significantly enhancing the patient's quality of life. Minimally invasive laparoscopic or robotic surgery is preferred for its reduced morbidity and shorter recovery time. Infertility management includes surgical relief of ejaculatory duct obstruction and assisted reproductive technologies when necessary. Regular follow-up is essential for monitoring recurrences. Future research should focus on long-term outcomes and standardized management protocols to improve patient quality of life.
- Open Access
- 22 November 2023
- Published by Elsevier in European Urology Open Science
- Vol. 57, S469
Telemedicine redefines follow-up for upper urinary tract trauma patients
- 22 November 2023
- Published by Elsevier in European Urology Open Science
- Vol. 57, S469
Open AccessTelemedicine redefines follow-up for upper urinary tract trauma patients